FDA approves darolutamide for non-metastatic castration-resistant prostate cancer
The Food and Drug Administration (FDA) approved darolutamide for non-metastatic castration-resistant prostate cancer. Approval of…
Browsing: ARAMIS trial
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- New studies clarify which genes may raise breast cancer risk
- The State of Cancer in New Zealand 2020
- COVID-19 and Telehealth: Practical guide for cancer clinicians
- FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma
- Mathematical method developed to predict cancer and drug-specific immunotherapy efficacy
- Ultrasound technique treats prostate cancer with minimal side effects
- Landmark research toward increasing survival rates for aggressive childhood cancer
- Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
